PubRank

Edward A Sausville

Author PubWeight™ 119.39‹?›

Top papers

Rank Title Journal Year PubWeight™‹?›
1 Identification of small molecule inhibitors of hypoxia-inducible factor 1 transcriptional activation pathway. Cancer Res 2002 2.97
2 Phase I and pharmacokinetic study of MS-275, a histone deacetylase inhibitor, in patients with advanced and refractory solid tumors or lymphoma. J Clin Oncol 2005 2.36
3 Issues and progress with protein kinase inhibitors for cancer treatment. Nat Rev Drug Discov 2003 2.32
4 Perifosine, a novel alkylphospholipid, inhibits protein kinase B activation. Mol Cancer Ther 2003 2.24
5 Phase 1 and pharmacologic study of MS-275, a histone deacetylase inhibitor, in adults with refractory and relapsed acute leukemias. Blood 2007 2.15
6 Synthesis and biological evaluation of novel curcumin analogs as anti-cancer and anti-angiogenesis agents. Bioorg Med Chem 2004 2.09
7 Mammalian target of rapamycin, a molecular target in squamous cell carcinomas of the head and neck. Cancer Res 2005 2.07
8 PRECEDENT: a randomized phase II trial comparing vintafolide (EC145) and pegylated liposomal doxorubicin (PLD) in combination versus PLD alone in patients with platinum-resistant ovarian cancer. J Clin Oncol 2013 1.92
9 Identification of small molecule inhibitors of anthrax lethal factor. Nat Struct Mol Biol 2003 1.86
10 Persistent activation of the Akt pathway in head and neck squamous cell carcinoma: a potential target for UCN-01. Clin Cancer Res 2004 1.83
11 The TSC2/mTOR pathway drives endothelial cell transformation induced by the Kaposi's sarcoma-associated herpesvirus G protein-coupled receptor. Cancer Cell 2006 1.63
12 In vivo antitumor efficacy of 17-DMAG (17-dimethylaminoethylamino-17-demethoxygeldanamycin hydrochloride), a water-soluble geldanamycin derivative. Cancer Chemother Pharmacol 2005 1.60
13 Subdural hematomas in patients with Philadelphia chromosome-positive acute lymphoblastic leukemia receiving imatinib mesylate in conjunction with systemic and intrathecal chemotherapy. Leuk Lymphoma 2011 1.53
14 Preclinical toxicity of a geldanamycin analog, 17-(dimethylaminoethylamino)-17-demethoxygeldanamycin (17-DMAG), in rats and dogs: potential clinical relevance. Cancer Chemother Pharmacol 2005 1.53
15 Akt plays a central role in sarcomagenesis induced by Kaposi's sarcoma herpesvirus-encoded G protein-coupled receptor. Proc Natl Acad Sci U S A 2004 1.52
16 Diagnostic markers that distinguish colon and ovarian adenocarcinomas: identification by genomic, proteomic, and tissue array profiling. Cancer Res 2003 1.51
17 Inhibition of nuclear factor-kappaB and target genes during combined therapy with proteasome inhibitor bortezomib and reirradiation in patients with recurrent head-and-neck squamous cell carcinoma. Int J Radiat Oncol Biol Phys 2005 1.44
18 Mining the National Cancer Institute's tumor-screening database: identification of compounds with similar cellular activities. J Med Chem 2002 1.43
19 Phase I clinical and pharmacokinetic study of flavopiridol administered as a daily 1-hour infusion in patients with advanced neoplasms. J Clin Oncol 2002 1.40
20 Novel small molecule inhibitors of botulinum neurotoxin A metalloprotease activity. Biochem Biophys Res Commun 2003 1.34
21 Comparison of 17-dimethylaminoethylamino-17-demethoxy-geldanamycin (17DMAG) and 17-allylamino-17-demethoxygeldanamycin (17AAG) in vitro: effects on Hsp90 and client proteins in melanoma models. Cancer Chemother Pharmacol 2005 1.33
22 Fluorinated 2-(4-amino-3-methylphenyl)benzothiazoles induce CYP1A1 expression, become metabolized, and bind to macromolecules in sensitive human cancer cells. Drug Metab Dispos 2004 1.32
23 SJG-136 (NSC 694501), a novel rationally designed DNA minor groove interstrand cross-linking agent with potent and broad spectrum antitumor activity: part 1: cellular pharmacology, in vitro and initial in vivo antitumor activity. Cancer Res 2004 1.28
24 Natural products and derivatives as leads to cell cycle pathway targets in cancer chemotherapy. Curr Cancer Drug Targets 2002 1.20
25 SJG-136 (NSC 694501), a novel rationally designed DNA minor groove interstrand cross-linking agent with potent and broad spectrum antitumor activity: part 2: efficacy evaluations. Cancer Res 2004 1.19
26 Antiangiogenic properties of 17-(dimethylaminoethylamino)-17-demethoxygeldanamycin: an orally bioavailable heat shock protein 90 modulator. Clin Cancer Res 2004 1.19
27 Ligand-directed surface profiling of human cancer cells with combinatorial peptide libraries. Cancer Res 2006 1.17
28 Determination of MS-275, a novel histone deacetylase inhibitor, in human plasma by liquid chromatography-electrospray mass spectrometry. J Chromatogr B Analyt Technol Biomed Life Sci 2004 1.13
29 Review of UCN-01 development: a lesson in the importance of clinical pharmacology. J Clin Pharmacol 2005 1.12
30 Aryl hydrocarbon receptor activation of an antitumor aminoflavone: basis of selective toxicity for MCF-7 breast tumor cells. Mol Cancer Ther 2004 1.12
31 Transcriptional regulation of the transforming growth factor beta type II receptor gene by histone acetyltransferase and deacetylase is mediated by NF-Y in human breast cancer cells. J Biol Chem 2001 1.10
32 Involvement of reactive oxygen species in adaphostin-induced cytotoxicity in human leukemia cells. Blood 2003 1.10
33 7-hydroxystaurosporine (UCN-01) inhibition of Akt Thr308 but not Ser473 phosphorylation: a basis for decreased insulin-stimulated glucose transport. Clin Cancer Res 2004 1.10
34 Flavopiridol-related proinflammatory syndrome is associated with induction of interleukin-6. Clin Cancer Res 2003 1.07
35 Clinical pharmacology of flavopiridol following a 72-hour continuous infusion. Ann Pharmacother 2003 1.07
36 Adaphostin-induced apoptosis in CLL B cells is associated with induction of oxidative stress and exhibits synergy with fludarabine. Blood 2004 1.06
37 Preclinical studies of vorinostat (suberoylanilide hydroxamic acid) combined with cytosine arabinoside and etoposide for treatment of acute leukemias. Clin Cancer Res 2009 1.05
38 Application of high-throughput, molecular-targeted screening to anticancer drug discovery. Curr Top Med Chem 2002 1.05
39 Perifosine, a novel alkylphospholipid, induces p21(WAF1) expression in squamous carcinoma cells through a p53-independent pathway, leading to loss in cyclin-dependent kinase activity and cell cycle arrest. Cancer Res 2002 1.05
40 Gene expression correlating with response to paclitaxel in ovarian carcinoma xenografts. Mol Cancer Ther 2004 1.05
41 17-(Allylamino)-17-demethoxygeldanamycin activity in human melanoma models. Anticancer Drugs 2004 1.04
42 In vitro combination treatment with perifosine and UCN-01 demonstrates synergism against prostate (PC-3) and lung (A549) epithelial adenocarcinoma cell lines. Clin Cancer Res 2004 1.04
43 Aryl hydrocarbon receptor mediates sensitivity of MCF-7 breast cancer cells to antitumor agent 2-(4-amino-3-methylphenyl) benzothiazole. Mol Pharmacol 2002 1.03
44 Synergistic antileukemic interactions between 17-AAG and UCN-01 involve interruption of RAF/MEK- and AKT-related pathways. Blood 2003 1.01
45 A mechanistic perspective of monoclonal antibodies in cancer therapy beyond target-related effects. Oncologist 2007 1.00
46 A phase I/II study of carfilzomib 2-10-min infusion in patients with advanced solid tumors. Cancer Chemother Pharmacol 2013 1.00
47 Components of the cell death machine and drug sensitivity of the National Cancer Institute Cell Line Panel. Clin Cancer Res 2004 1.00
48 Effects of the Bcr/abl kinase inhibitors STI571 and adaphostin (NSC 680410) on chronic myelogenous leukemia cells in vitro. Blood 2002 0.98
49 Preclinical evaluation of amino acid prodrugs of novel antitumor 2-(4-amino-3-methylphenyl)benzothiazoles. Mol Cancer Ther 2002 0.97
50 Cytotoxicity and apoptosis of benzoquinones: redox cycling, cytochrome c release, and BAD protein expression. Biochem Pharmacol 2003 0.95
51 Inhibition of mitochondrial respiration as a source of adaphostin-induced reactive oxygen species and cytotoxicity. J Biol Chem 2007 0.94
52 A phase I trial of UCN-01 and prednisone in patients with refractory solid tumors and lymphomas. Cancer Chemother Pharmacol 2009 0.94
53 Phase I study of folate conjugate EC145 (Vintafolide) in patients with refractory solid tumors. J Clin Oncol 2012 0.94
54 Induction of apoptosis in human leukemia cells by the tyrosine kinase inhibitor adaphostin proceeds through a RAF-1/MEK/ERK- and AKT-dependent process. Oncogene 2004 0.94
55 DNA repair protein levels vis-à-vis anticancer drug resistance in the human tumor cell lines of the National Cancer Institute drug screening program. Anticancer Drugs 2002 0.93
56 Antitumor activity of UCN-01 in carcinomas of the head and neck is associated with altered expression of cyclin D3 and p27(KIP1). Clin Cancer Res 2002 0.92
57 A high-throughput screen for identification of molecular mimics of Smac/DIABLO utilizing a fluorescence polarization assay. Anal Biochem 2003 0.91
58 Clinical pharmacokinetics and exposure-toxicity relationship of a folate-Vinca alkaloid conjugate EC145 in cancer patients. J Clin Pharmacol 2009 0.91
59 Preclinical modeling of combination treatments: fantasy or requirement? Ann N Y Acad Sci 2005 0.91
60 Drug discovery targeting Chk1 and Chk2 kinases. Prog Cell Cycle Res 2003 0.89
61 First-in-human phase 1 study of filanesib (ARRY-520), a kinesin spindle protein inhibitor, in patients with advanced solid tumors. Invest New Drugs 2015 0.89
62 Clinical and laboratory studies of the novel cyclin-dependent kinase inhibitor dinaciclib (SCH 727965) in acute leukemias. Cancer Chemother Pharmacol 2013 0.88
63 "Vasocrine" formation of tumor cell-lined vascular spaces: implications for rational design of antiangiogenic therapies. Cancer Res 2003 0.88
64 Safety, efficacy, pharmacokinetics, and pharmacodynamics of the combination of sorafenib and tanespimycin. Clin Cancer Res 2010 0.88
65 Biodistribution of HPMA copolymer-aminohexylgeldanamycin-RGDfK conjugates for prostate cancer drug delivery. Mol Pharm 2009 0.88
66 Phospho-p70S6K/p85S6K and cdc2/cdk1 are novel targets for diffuse large B-cell lymphoma combination therapy. Clin Cancer Res 2009 0.87
67 Flavopiridol, a novel cyclin-dependent kinase inhibitor, in clinical development. Ann Pharmacother 2002 0.87
68 Establishing connections between microarray expression data and chemotherapeutic cancer pharmacology. Mol Cancer Ther 2002 0.87
69 Ten-day decitabine as initial therapy for newly diagnosed patients with acute myeloid leukemia unfit for intensive chemotherapy. Leuk Lymphoma 2014 0.86
70 Validation of tumour models for use in anticancer nanomedicine evaluation: the EPR effect and cathepsin B-mediated drug release rate. Cancer Chemother Pharmacol 2013 0.86
71 Anti-tumor drug candidate 2-(4-amino-3-methylphenyl)-5-fluorobenzothiazole induces single-strand breaks and DNA-protein cross-links in sensitive MCF-7 breast cancer cells. Cancer Chemother Pharmacol 2005 0.86
72 Histone deacetylase inhibitor pharmacodynamic analysis by multiparameter flow cytometry. Ann Clin Lab Sci 2005 0.86
73 Genotoxic profiling of MCF-7 breast cancer cell line elucidates gene expression modifications underlying toxicity of the anticancer drug 2-(4-amino-3-methylphenyl)-5-fluorobenzothiazole. Mol Pharmacol 2003 0.85
74 Induction of CYP1A1 in tumor cells by the antitumor agent 2-[4-amino-3-methylphenyl]-5-fluoro-benzothiazole: a potential surrogate marker for patient sensitivity. Mol Cancer Ther 2003 0.85
75 Interspecies differences in plasma protein binding of MS-275, a novel histone deacetylase inhibitor. Cancer Chemother Pharmacol 2005 0.85
76 Targetable HPMA copolymer-aminohexylgeldanamycin conjugates for prostate cancer therapy. Pharm Res 2009 0.85
77 In vivo models for experimental therapeutics relevant to human cancer. Cancer Res 2004 0.85
78 Synthesis, structure-activity relationship, and p210(bcr-abl) protein tyrosine kinase activity of novel AG 957 analogs. Bioorg Med Chem 2005 0.84
79 The broad-range cyclin-dependent kinase inhibitor UCN-01 induces apoptosis in colon carcinoma cells through transcriptional suppression of the Bcl-x(L) protein. Oncogene 2005 0.84
80 A phase II study of temozolomide in patients with advanced aerodigestive tract and colorectal cancers and methylation of the O6-methylguanine-DNA methyltransferase promoter. Mol Cancer Ther 2013 0.83
81 Effects of alpha1-acid glycoprotein on the clinical pharmacokinetics of 7-hydroxystaurosporine. Clin Cancer Res 2004 0.83
82 Molecular mechanism of adaphostin-mediated G1 arrest in prostate cancer (PC-3) cells: signaling events mediated by hepatocyte growth factor receptor, c-Met, and p38 MAPK pathways. J Biol Chem 2006 0.83
83 In vitro and in vivo evaluations of the tyrosine kinase inhibitor NSC 680410 against human leukemia and glioblastoma cell lines. Cancer Chemother Pharmacol 2002 0.82
84 Reducing undesirable hepatic clearance of a tumor-targeted vinca alkaloid via novel saccharopeptidic modifications. J Pharmacol Exp Ther 2010 0.82
85 Phase I study of UCN-01 and perifosine in patients with relapsed and refractory acute leukemias and high-risk myelodysplastic syndrome. Invest New Drugs 2013 0.81
86 Linking the growth inhibition response from the National Cancer Institute's anticancer screen to gene expression levels and other molecular target data. Bioinformatics 2003 0.81
87 Aurora kinases dawn as cancer drug targets. Nat Med 2004 0.81
88 Clinical pharmacology and pharmacogenetics of flavopiridol 1-h i.v. infusion in patients with refractory neoplasms. Anticancer Drugs 2003 0.81
89 Factors affecting the pharmacokinetic profile of MS-275, a novel histone deacetylase inhibitor, in patients with cancer. Invest New Drugs 2006 0.80
90 Versipelostatin: unfolding an unsweetened death. J Natl Cancer Inst 2004 0.80
91 Nucleotide excision repair protein levels vis-à-vis anticancer drug resistance in 60 human tumor cell lines. Ai Zheng 2002 0.80
92 Preclinical models for defining efficacy of drug combinations: mapping the road to the clinic. Mol Cancer Ther 2003 0.80
93 Disparities in black and white patients with multiple myeloma referred for autologous hematopoietic transplantation: a single center study. Cancer 2014 0.80
94 Cytotoxicity of RH1: NAD(P)H:quinone acceptor oxidoreductase (NQO1)-independent oxidative stress and apoptosis induction. Anticancer Drugs 2005 0.79
95 A phase I and pharmacokinetic study of oral perifosine with different loading schedules in patients with refractory neoplasms. Cancer Chemother Pharmacol 2014 0.78
96 Asparaginase in the treatment of non-ALL hematologic malignancies. Cancer Chemother Pharmacol 2014 0.78
97 Schistocytes, echinocytes, iron deficiency anemia, and thrombocytopenia - hematologic manifestations of splenic angiosarcoma. Arch Iran Med 2013 0.77
98 Determination of drug synergism between the tyrosine kinase inhibitors NSC 680410 (adaphostin) and/or STI571 (imatinib mesylate, Gleevec) with cytotoxic drugs against human leukemia cell lines. Cancer Chemother Pharmacol 2003 0.77
99 Transcriptional profiling identifies altered intracellular labile iron homeostasis as a contributing factor to the toxicity of adaphostin: decreased vascular endothelial growth factor secretion is independent of hypoxia-inducible factor-1 regulation. Clin Cancer Res 2005 0.77
100 Comparative Analysis of Methods for Detecting Isocitrate Dehydrogenase 1 and 2 Mutations and Their Metabolic Consequence, 2-Hydroxyglutarate, in Different Neoplasms. Appl Immunohistochem Mol Morphol 2016 0.76
101 The antitumor drug candidate 2-(4-amino-3-methylphenyl)-5-fluorobenzothiazole induces NF-kappaB activity in drug-sensitive MCF-7 cells. Anticancer Drugs 2005 0.76
102 Atiprimod is an inhibitor of cancer cell proliferation and angiogenesis. J Exp Ther Oncol 2004 0.76
103 Respecting cancer drug transportability: a basis for successful lead selection. J Natl Cancer Inst 2006 0.76
104 Unbalanced 11;18 translocation in an acute erythroid leukemia after radioactive iodine therapy. Cancer Genet 2013 0.76
105 STI571 (imatinib mesylate): the tale of a targeted therapy. Anticancer Drugs 2002 0.76
106 Homology model of the CDK1/cyclin B complex. J Biomol Struct Dyn 2005 0.76
107 Genes in the service of therapeutic index: progress for virus-directed enzyme prodrug therapy. J Clin Oncol 2004 0.75
108 Promises from trametinib in RAF active tumors. N Engl J Med 2012 0.75
109 Phase 1 dose-escalation, pharmacokinetic, and cerebrospinal fluid distribution study of TAK-285, an investigational inhibitor of EGFR and HER2. Invest New Drugs 2013 0.75
110 Indifferently pursued or unowned drugs: who should lead where companies do not tread? J Clin Oncol 2005 0.75
111 Mitochondrial function as an emerging 'target of interest' for cancer treatment. Curr Opin Investig Drugs 2009 0.75
112 Is another bcr-abl inhibitor needed for chronic myelogenous leukemia? Clin Cancer Res 2003 0.75
113 Treatment of catheter-related deep vein thrombosis in patients with acute leukemia with anticoagulation. Leuk Lymphoma 2015 0.75
114 Benzodithiophenes induce differentiation and apoptosis in human leukemia cells. Cancer Res 2005 0.75
115 Cytotoxicities of three rebeccamycin derivatives in the National Cancer Institute screening of 60 human tumor cell lines. Anticancer Drugs 2005 0.75
116 Synthesis and antitumour evaluation of 4-bromophenyl semicarbazones. Arzneimittelforschung 2002 0.75
117 Overview: the art of cancer drug screening: molecular target versus milieu-based screens. Curr Opin Investig Drugs 2002 0.75
118 Differential gene expression as a potential classifier of 2-(4-amino-3-methylphenyl)-5-fluorobenzothiazole-sensitive and -insensitive cell lines. Mol Pharmacol 2005 0.75
119 Meeting report on the Ninth Conference on Cancer Therapy with Antibodies and Immunoconjugates. Cancer Res 2003 0.75